Introduction c-Myc is an oncogenic transcription factor involved in the control of cell proliferation, differentiation, and apoptosis. c-Myc heterodimerizes with the protein Max, and the dimer binds to a specific DNA sequences in the regulatory regions of target genes. The list includes genes involved in cell cycle progression (particularly in G1 phase), energetic metabolism, and protein synthesis (both at translational control and ribosome biogenesis) (Dang, 1999; Grandori et al., 2000; Lutz et al., 2002) .
Consistent with its positive effect in cell growth, deregulated expression of c-Myc either by gene amplification or rearrangement affecting regulatory regions is a common finding in human cancer, and in most cases it has been associated with disease progression (Nesbit et al., 1999) . Since c-Myc is engaged in cell cycle progression (Mateyak et al., 1997; de Alboran et al., 2001) , its deregulation in cancer is consistent with its transforming activity in many cellular models, alone or in cooperation with other oncoproteins (Grandori and Eisenman, 1997; Oster et al., 2002) . Therefore, the mechanisms by which c-Myc stimulates cell proliferation have received much attention.
c-Myc acts as a competence factor allowing the quiescent cell enter the cell cycle (Grandori and Eisenman, 1997; Lutz et al., 2002) . Although it is long recognized that mitogenic stimulation of quiescent cells by growth factors induces c-Myc expression, the pathways leading to the activation of Myc gene are unclear as yet. It has been shown that Myc expression requires the activation of some protein tyrosine kinases as Src, Jak2, and Abl in response to growth factors (Bowman et al., 2001; Fresno Vara et al., 2001; Xie et al., 2002) . However, the data accumulated to date suggest that the prevalent kinase involved in c-Myc upregulation may depend on the cellular type under study. Most studies on kinase-mediated activation of c-Myc expression have been carried out in fibroblasts. However, little is known about the pathways by which mitogenic factors activate c-Myc gene in lymphoid cells, despite the frequent finding of c-Myc deregulation in lymphomas (Nesbit et al., 1999; Sanchez-Beato et al., 2003) and the demonstrated requirement of c-Myc for murine Bcell mitogenic response and survival (Wu et al., 1996; de Alboran et al., 2001) .
We have used a genetically defined cell system to dissect the pathways leading to the induction of c-Myc expression by growth factors, namely W53 cells, a cell line derived from the murine lymphoid BaF-3 cells stably transfected with the prolactin receptor (PRLR) (Morales et al., 1999) . Prolactin (PRL) is capable of eliciting a mitogenic response in W53 cells, and we previously demonstrated that the expression of c-Myc in these cells in response to PRL required Src activation (Fresno Vara et al., 2001) . In this work, we studied the pathways downstream from Src activation that lead to proliferation and c-Myc upregulation. We found that in this system PRL activates Erk1/2 and the PI3K-dependent Akt and 70S6K serine/threonine kinases, but only Akt activation was required for the activation of c-Myc expression. Akt signalled through the forkhead transcription factor FKHRL1 and glycogen synthetase kinase 3 (GSK3), both contributing to c-Myc upregulation. Moreover, ectopic expression of c-Myc could overcome the cell growth arrest effect promoted by Akt inactivation.
Results
We have previously shown that PRL activates proliferation and c-Myc expression in lymphoid W53 cells (derived from BaF-3 by transfection of PRL receptor) (Fresno Vara et al., 2001) . Here, we set out to analyse the mechanisms by which PRL controls expression of cMyc through a systematic analysis of the signalling pathways activated by PRLR. As Src family kinases are required for PRL induction of cell proliferation (Fresno Vara et al., 2001) , we first analysed the involvement of Src in the upregulation of Myc gene transcript by using the Src inhibitor PP1. We found that inhibition of Src kinases by PP1 greatly diminished PRL induction of cMyc and c-Fos transcripts (Figure 1) . Thus, the induction of these genes by PRL is at least partially dependent on Src activity.
Activation of the MAPK pathway is a general requisite for cell proliferation in many different cell types (Roovers and Assoian, 2000; Wilkinson and Millar, 2000) . We have previously shown that PRL stimulated Erk1/2 in W53 cells (Fresno Vara et al., 2001) ; therefore, we looked for the role of the MAPK pathway in cell proliferation, and expression of c-Myc and c-Fos mRNAs induced by PRL. To this end, exponentially growing cultures of W53 cells were treated with increasing concentrations of PD184352, a specific inhibitor of Mek1/2 activity (Sebolt-Leopold et al., 1999; Davies et al., 2000) , in the presence of PRL (5 ng/ ml) for 24 h, and [ 3 H]thymidine was added for the last 4 h, as described in Materials and methods. These assays showed that PD184352 inhibited cell proliferation in a dose-dependent manner ( Figure 2a ). Next, we tested whether there were crosstalks between the MAPK pathways and other signalling pathways stimulated by PRL in W53 (Fresno Vara et al., 2001) . We analysed the effect of PD184352 (2.5 mM) on PRL (100 ng/ml) stimulation of the MAPK pathway. Pretreatment of cells for 2 h with this inhibitor of Mek1/2 activity abolished PRL activation of Erk1/2 (Figure 2b, pErk1/ 2-Erk2 panels). The MAPK pathway did not appear to crosstalk with Jak2/Stat5, as PRL stimulation of Stat5 phosphorylation was unaltered by PD184352 ( Figure 2b , pStat5-Stat5 panels). Similarly, PRL activation of the PI3K-dependent Akt and p70S6K serine/threonine kinases was also detected after pretreatment of W53 cells with PD184352 ( Figure 2b , pAkt-Akt and pp70S6K-p70S6K, respectively).
The expression of c-Myc and c-Fos was determined by Northern analysis from total RNA extracted from cells that at resting state were treated for 2 h with PD184352 (2.5 mM) prior to stimulation with PRL (100 ng/ml) for different periods of time. The expression of c-Myc mRNA was not affected by the inhibition of the MAPK pathway, as its levels of expression, which increased to a maximum at 60 min, were unaltered by treatment of cells with PD184352, although the peak of expression was delayed with respect to control (Figure 2c ). In contrast, PRL activation of c-Fos mRNA expression was dependent on Erk1/2 activation, as it was abolished by PD184352 (Figure 2c ).
The Src kinases mediate PRL induction of PI3K-dependent p70S6K and Akt activation in W53 cells (Fresno Vara et al., 2001) . To determine the role of the Figure 1 Role of Src kinases on PRL induction of c-Myc and cFos expression. Serum-starved cultures of W53 cells were treated with Src kinase selective inhibitor PP1 (10 mM) or DMSO (as a control) for 2 h prior to stimulation with PRL (100 ng/ml). Aliquots of cells were collected at the indicated times, total RNA was extracted, and the mRNA expression of c-Myc and c-Fos was analysed by Northern blot as described in Materials and methods. As a loading control, the rRNAs transferred to the filter were visualized by methylene blue staining (lower panel). The data are representative of three separate experiments PI3K-dependent pathways on the proliferative mechanisms of PRL, the PI3K inhibitor LY294002 was used. The addition of LY294002 to exponentially growing PRL-stimulated W53 cells inhibited [ 3 H]thymidine incorporation in a dose-dependent manner ( Figure 3a) . As expected, LY294002 (5 mM) abolished PRL (100 ng/ ml) stimulation of the PI3K-dependent p70S6K and Akt kinases, but it did not inhibit the activation of Mek1/2-Erk1/2 pathway or the Jak2-dependent phosphorylation of Stat5 (Figure 3b ). These results indicate that the activation of the MAPK and Jak2/Stat5 pathways by PRL is independent of the PI3K activity in W53 cells.
Since PRL-induced W53 proliferation is PI3K dependent, we explored for its role on PRL induction of c-Fos and c-Myc mRNAs expression. Northern analysis of W53 cells pretreated with LY294002 (5 mM) prior to PRL (100 ng/ml) stimulation revealed that inhibition of PI3K activity blocked PRL induction of c-Myc expression (Figure 3c ). In contrast, it did not alter PRL stimulation of c-Fos expression (Figure 3c ).
The former results strongly argued an involvement of PI3K in the control of c-Myc expression in response to PRL. Thus, we investigated the role of the PI3K-dependent Akt and p70S6K kinases on c-Myc mRNA expression. Since p70S6K depends on mTOR for activation (Ferrari et al., 1993; Calvo et al., 1994; Weng et al., 1995) , we studied the effect of the mTOR inhibitor rapamycin on PRL stimulated W53 cell proliferation. Rapamycin had a very modest inhibitory effect on W53 proliferation. At the highest concentration used (100 nM), the inhibition of [ 3 H]thymidine incorporation was smaller than 40% ( Figure 4a ). As expected, rapamycin abolished PRL activation of p70S6K ( Figure 4b ). In contrast, it had no effect on PRL activation of both Akt and Stat5 phosphorylation (Figure 4b ). Interestingly, rapamycin reinforced PRL stimulation of Erk1/2, without an apparent effect on Mek1/2 activation by PRL (Figure 4b ).
PRL stimulation of c-Fos and c-Myc mRNAs expression was independent of p70S6K activation, as it was not modified by treatment of W53 cells with rapamycin ( Figure 4c ). When results were normalized with the amounts of rRNA, the signal ratios in PRL þ rapamycin-treated cells were similar to those in cells treated with PRL alone (data not shown), indicating that rapamycin did not modify c-Fos and c-Myc mRNAs expression.
To analyse the role of Akt on c-Myc mRNA, we challenged the inhibitory effect of LY294002 on c-Myc by overexpression of a HA-tagged Akt mutant harbouring a myristoylation signal (Akt-myr), which targets Akt to the membrane. Full Akt activation requires both membrane location and subsequent phosphorylation by PDK (Alessi et al., 1996; Bellacosa et al., 1998) . To determine the effect of PD184352 in PRL activation of Mek1/2, Erk1/2, Stat5, p70S6K, and Akt, resting cells were incubated in the presence of DMSO (control) or PD184352 (2.5 mM) for 2 h prior to stimulation with PRL (100 ng/ ml) for the indicated times. WB using anti-phospho-specific antibodies measured the degree of activation of Mek1/2, Erk1/2, Stat5, p70S6K, and Akt in cell extracts (20 mg of proteins). Lower panels show the stripped membranes reprobed with their specific antibodies as loading controls. (c) Serum-starved cultures of W53 cells were treated with PD184352 (2.5 mM) or DMSO (as a control) for 2 h and then stimulated with PRL (100 ng/ml). Aliquots of cells were collected at the indicated times, and the mRNA expression of cMyc and c-Fos was analysed as described in Figure 1 . The data are representative of three separate experiments W53 cells were transfected with either wild-type Akt (Akt-wt) or Akt-myr to generate two new stable cell lines. We tested them for the expression of exogenous Akt by Western blot of total cell extracts with anti-HA Y-11 polyclonal antibody. The results showed that these cell lines expressed similar levels of Akt-wt and To determine the effect of PI3K inhibition by LY294002 in PRL activation of p70S6K, Akt, Stat5, Mek1/2, and Erk1/2, resting cells were incubated in the presence of DMSO (control) or LY294002 (5 mM) for 2 h prior stimulation with PRL (100 ng/ml) for the indicated times. The degree of activation of these kinases was measured by Western blot as described in Figure 2b . (c) W53 serum-starved cultures were treated with LY294002 (5 mM) or DMSO (as a control) for 2 h and then stimulated with PRL (100 ng/ ml). Aliquots of cells were collected at the indicated times, and the mRNA expression of c-Myc and c-Fos was analysed as described in Materials and methods. The data are representative of three separate experiments To determine the effect of rapamycin in PRL activation of p70S6K, Akt, Stat5, Mek1/2, and Erk1/2, resting cells were incubated in the presence of DMSO (control) or rapamycin (100 nM) for 2 h prior stimulation with PRL (100 ng/ml) for the indicated times. The degree of activation of these kinases was measured by Western blot as described in Figure 2b . (c) W53 serum-starved cultures were treated with rapamycin (100 nM) or DMSO (as a control) for 2 h prior stimulation with PRL (100 ng/ ml). Aliquots of cells were collected at the indicated times, and the mRNA expression of c-Myc and c-Fos was analysed as described in Materials and methods. The data are representative of three separate experiments Akt-myr, respectively ( Figure 5a ). However, the total levels of pAkt were higher in cells expressing the Aktmyr than in cells expressing the Akt-wt (Figure 5b ). Then, we analysed the effect of the PI3K inhibitor It has been recently demonstrated that Akt phosphorylates and inactivates the forkhead transcription factor FKHRL1, and promotes its nuclear exclusion (Brunet et al., 1999) . We analysed whether PRL stimulation of W53 cells provokes nuclear exclusion of FKHRL1 by immunofluorescence. The results showed that while in quiescent cells FKHRL1 was mainly located in the nucleus, upon PRL stimulation FKHRL1 translocational to the cytoplasm ( Figure 6a ). In contrast, and as expected from the Akt phosphorylation observed in immunoblots, PRL induced the Akt translocation to the nucleus, thus confirming the PRL-mediated activation of Akt (Figure 6b ). Consistently with this observation, PRL stimulation induced phosphorylation of FKHRL1 that was inhibited by LY294002 ( Figure 7a ). We then tested the effect of Akt-CAAX Box expression. In W53-Akt-CAAX Box Tet-On cells without doxycycline treatment (as in Figure 5e ), PRL stimulated phosphorylation of FKHRL1. Induction of Akt-CAAX Box expression by doxycycline caused inhibition of FKHRL1 phosphorylation (Figure 7b ). This effect was concomitant with the inhibition of c-Myc expression shown previously (Figure 5e) .
To determine the possible role of FKHRL1 on c-Myc expression in W53 cells, we used an active mutant of FKHRL1, in which the three inhibitory phosphorylation sites were mutated to alanines, FKHRL1-A3 (Dijkers et al., 2002) . Cells were transiently transfected with the c-Myc promoter luciferase reporter construct (Lee and Ziff, 1999) together with pSG5-FKHRL1-A3, or the empty plasmid as control. The luciferase activity was measured in unstimulated and PRL-stimulated cells, and the fold induction of the promoter was Akt also regulates c-Myc levels by controlling the activity of GSK3 through phosphorylation, which in turn phosphorylates c-Myc at Thr-58 and facilitates its ubiquitin-mediated proteolysis (Gregory and Hann, 2000; Sears et al., 2000; Gregory et al., 2003) . Experiments were then set to analyse the contribution of the pathway Akt/GSK3 to the expression of c-Myc. When W53 cells were stimulated with PRL (100 ng/ml for 30 min), the phosphorylation of GSK3 was observed clearly; inhibition of Akt activation by LY29004 blocked GSK3 phosphorylation ( Figure 7d ). As lithium salts and SB415286 have been described as selective inhibitors of GSK3 (Sayas et al., 1999; Davies et al., 2000; Gregory et al., 2003; Barry et al., 2003; Orme et al., 2003) , these two compounds were used to determine the contribution of this kinase to the stability of c-Myc. Quiescent W53 cells were treated with 5 mM lithium chloride or 5 mM SB415286 for 2 h prior to PRL stimulation (100 ng/ml for 60 min), then protein extracts were prepared and the expression of c-Myc and atubulin (as a loading control) were determined by Western blot. The results showed that inhibition of GSK3 by lithium chloride or by SB415286 allowed to detect basal levels of c-Myc in unstimulated cells as compared to untreated W53 (Figure 7e ). When cells were stimulated with PRL, both selective inhibitors of GSK3 induced a clear increase of c-Myc levels as compared with untreated cells (Figure 7e ), demonstrating that the pathway Akt/GSK3 is involved in the levels of c-Myc expression in PRL-stimulated W53 cells.
To determine if the expression of myristoylated Akt had also effects in cell survival and proliferation, we next studied the cell cycle by flow cytometry analysis. Cell cultures were placed in medium containing 1% horse serum, in the absence or presence of PRL (100 ng/ ml) and DMSO or LY294002 (5 mM), and 24 h later cells were fixed and stained with propidium iodide (PI) as described in Materials and methods. PRL is a cell survival and mitogenic factor in W53 and, as expected, in its absence cells became apoptotic and died (Morales et al., 1999) . Akt-wt expressing W53 cells did not survive in the absence of PRL and most of them died within 24 h period, whereas no cells were found in S or G 2 -M phases (Figure 8a, DMSO) . In contrast, myristoylated Akt overcame the absence of PRL and a large portion of the cells entered the cycle with 18% of them in S and 7% in G2-M phases of the cell cycle (Figure 8b, DMSO) . Treatment with LY294002 (5 mM) in the absence of PRL did not modify the response of cell expressing Akt-wt, as most of the cells were dead (Figures 8a, LY294002 ). In contrast, LY294002 treatment of cells expressing Aktmyr did not significantly modify the profile observed in untreated cells (compare Figure 8b DMSO and LY294002), except for a small increase of cells in G0-G1 and a decrease of the portion of cells in S phase (Figure 8b ). This profile is in sharp contrast to the one observed for W53 Akt-wt cells (Figure 8a ). The addition of PRL made both cell types to grow, although Aktmyr-expressing cells showed a higher rate of proliferation than Akt-wt-expressing cells, as confirmed by a higher percentage of cells in S phase, 46 versus 27% (Figure 8a W53 Akt-wt, and Figure 8b W53 Akt-myr). Treatment of cells with LY294002 decreased cell proliferation and caused accumulation of cells in G0-G1. This effect was very pronounced in cells expressing Akt-wt, showing an increase in G0-G1 phase population from 58 to 80%, and an important decrease in the percentage of cells in S phase from 27 to 17% (Figure 8a ). In cells expressing myristoylated Akt, addition of LY294002 in the presence of PRL caused a small decrease in S phase from 46 to 42% (Figure 8b ). To confirm these observations, we analysed the apoptotic response as a consequence of PRL depletion, measured by degradation of Parp (poly(ADP-ribose) polymerase), a caspase-3 substrate; in Akt-wt-expressing cells, the native form of Parp (p116) was degraded by caspase activation to the proteolytic p85 form (Figure 9 ). In contrast, expression of myristoylated Akt blocked the caspase activation and Parp degradation (Figure 9 ). These results confirmed the apoptosis protecting effect of Akt activity in cells deprived of PRL.
Consequently with the fact that myristoylated Akt facilitated c-Myc expression and cell survival, we next analysed the cellular response of c-Myc overexpression. W53 cells were electroporated with pCEFL-Myc or with the empty vector as control. After 2 days, cells were selected with 2 mg/ml of G418, and after 3 weeks (Figure 10a , upper panel). To confirm the overexpression of c-Myc in these cells, the Western blot assay was carried out with C19 anti-c-Myc, which recognizes both the endogenous mouse protein and the exogenously expressed human Myc (Figure 10a , middle panel). As a loading control, the Western blot was hybridized with anti-a-tubulin (Figure 10a, lower panel) . Then, we analysed the effect of the PI3K inhibitor LY294002 (5 mM) on cell proliferation in W53 cells that overexpressed c-Myc. After 24 h of treatment, cells were fixed and stained with PI and analysed by flow cytometry as above. The results showed that cells overexpressing c-Myc (W53-Myc) maintained active proliferation as compared to cells transfected with the empty vector (W53-Vo). Myc caused an increase in S phase of the cell cycle as compared to control cells (Figure 10b , PRL þ DMSO panels). Challenging both cell types with LY294002 reduced cell growth. However, in control cells the effect was more pronounced than in Myc-expressing cells, as the S phase decreased and cells had a tendency to accumulate in G0-G1 phase (Figure 10b , W53-Vo). Overexpression of Myc overcame the arresting effect of the PI3K inhibitor, as around 40% of the cell population still actively synthesized DNA, in contrast to the 20% of cells in S phase in the W53-Vo cells (Figure 10b ).
Discussion
Induction of c-Myc expression is an essential event elicited by the addition of growth factors to resting cells (Rohn et al., 1998; Grandori et al., 2000; Lutz et al., 2002; Oster et al., 2002) . We have previously shown that the Src kinases mediate PRL induction of c-Myc expression and proliferation in W53 cells (Fresno Vara Figure 8 Effect of LY294002 on survival and proliferation of Akt-wt-and Akt-myr-expressing W53 cells. Exponentially growing W53 Akt-wt and W53 Akt-myr cells were transferred in a 1% horse serum-containing medium supplemented with DMSO (as a control), LY294002 (5 mM), PRL (100 ng/ml) þ DMSO, or PRL þ LY294002. After 24 h, cells were fixed and stained with PI and analysed by flow cytometry. The percentage of cells in G0-G1, S, and G2-M phases was calculated by ModFitLT V2.0 computer program. The data are representative of three separate experiments Figure 9 Effect of LY294002 on apoptosis of Akt-wt and Aktmyr expressing W53 cells. Exponentially growing W53 Akt-wt and W53 Akt-myr cells were transferred in a 1% horse serumcontaining medium supplemented with DMSO (as a control), LY294002 (5 mM), PRL (100 ng/ml) þ DMSO, or PRL þ LY294002. After 24 h, cells were lysed, and from 25 mg protein extracts, the expression of native Parp (p116) or proteolytic Parp product (p85) was determined by Western blot as described in Materials and methods. As a loading control, the stripped membrane was reprobed with anti-a-tubulin Activation of Erk1/2 is essential for PRL induction of W53 proliferation, as inhibition of Mek1/2 activity by PD184352 (Sebolt-Leopold et al., 1999; Davies et al., 2000) resulted in abrogation of Erk1/2 activation and inhibition of cell proliferation. In contrast, Erk1/2 is not required for PRL induction of c-Myc mRNA expression. Expression of c-Fos mRNA, which is mediated by Src kinases in W53 PRL-stimulated cells, is also an Erk1/2 dependent process, as is abolished by PD184352. This result is consistent with the fact that the c-Fos promoter contains responsive elements controlled by the Ras/MAPK pathway (Shaulian and Karin, 2001) . It should be noted that inhibition of Src kinases activity by PP1 did not alter PRL activation of Erk1/2 in W53 cells (Fresno Vara et al., 2001 ), but we found (Figure 1 ) it significantly decreased c-Fos upregulation, suggesting that Src also activates c-Fos transcription. This is not unprecedented, as Src-mediated induction of c-Fos has been previously found in fibroblasts and endothelial cells (Simonson et al., 1996; Cheriyath et al., 2002) .
As indicated above, stimulation of W53 cells with PRL leads to the activation of the Src kinases, which in turn stimulates the PI3K-dependent p70S6K and Akt (Fresno Vara et al., 2001 ). In this model system, PI3K activity was a requisite for cell growth, as LY294002 decreased PRL stimulation of [ 3 H]thymidine incorporation in a dose-dependent manner, with no signs of apoptosis. PI3K was also necessary for PRL induction of c-Myc because LY294002 inhibited its expression. The Jak2/Stat5 or the Erk1/2 pathways did not mediate these actions of PI3K, as their activation by PRL was not modified in the presence of LY294002. Similarly, PI3K seems to be necessary for growth hormone induction of c-Myc expression (Jeay et al., 2001) . In these cells, PRL induction of c-Fos expression mediated by Src kinases was independent of PI3K as it was insensitive to LY294002.
Further down on the signalling cascade, we investigated the role of PI3K-dependent serine/threonine p70S6K and Akt kinases on PRL control of c-Myc expression. Using rapamycin we were able to block PRL induction of mTOR, the kinase responsible for p70S6K activation. This inhibition had a minor effect on cell proliferation, as at the highest concentration of rapamycin used (100 nM), the reduction on [ 3 H]-thymidine incorporation was only 30%, despite the complete block of p70S6K activation. Since rapamycin had no effect in PRL stimulation of Akt, Stat5, and Mek1/2, mTOR/ p70S6k pathway did not have a crosstalk with these other signalling pathways.
We next analysed the possible role of Akt in the control of c-Myc expression by PRL. To this end, we challenged the inhibitory effect of LY294002 on c-Myc by expressing a mutant of Akt targeted to the membrane by a myristoylation signal (myristoylated Akt, Aktmyr). This protein is considered as a constitutively activated Akt form, and in the absence of PRL, its degree of activation was higher than the Akt-wt expressed to similar level in W53 cells. When W53-Akt-wt and W53-Akt-myr were stimulated with PRL, we observed a clear expression of c-Myc in both cases. However, upon inhibition of PI3K by LY294002, W53-Akt-wt lost c-Myc expression, while W53-Akt-myr cells were partially resistant to PI3K inhibition. Consistently, doxycycline-induced expression of the dominantnegative mutant of Akt, Akt-CAAX Box (Dufner et al., 1999) , in W53-Akt-CAAX Box Tet-On cells inhibited expression of c-Myc. PRL stimulation of Akt facilitated its translocation to the nucleus where it phosphorylates transcription factors and modulates gene expression. Akt phosphorylates FKHRL1 transcription factors, causing its nuclear exclusion (Brunet et al., 1999) . Here, we observed that PRL stimulation of W53 activated FKHRL1 phosphorylation and nuclear exclusion, while treatment with LY294002 inhibited phosphorylation of this forkhead. In concordance with this result, inducible expression of Akt-CAAX Box blocked PRL stimulation of FKHRL1. This transcription factor controls the expression of p27 KIP1 , Bim, and cyclins D, promoting cell proliferation and survival (Dijkers et al., 2000; Dijkers et al., 2002; Schmidt et al., 2002) . Inactivation of forkhead transcription factors by Akt could be related to the observed c-Myc upregulation. This would imply that c-Myc is being repressed by forkhead and that this repression is alleviated upon phosphorylation by activated Akt. Recent reports based on microarray-based profiling and Myc promoter studies (Alvarez et al., 2001; Ramaswamy et al., 2002) did not reveal changes in Myc expression in cells expressing activated forms of forkhead transcription factors. We found that the expression of a phosphorylation-deregulated mutant of this transcription factor, FKHRL1 A3, where the Akt phosphorylation residues were mutated into alanines (Brunet et al., 1999) , negatively regulates c-Myc expression upon PRL stimulation of W53 cells. This is consistent with the role of this transcription factor in the maintenance of cellular resting state.
We have further studied the link between Akt and cMyc investigating the role of GSK3. It is also likely that Akt upregulates c-Myc by inactivation of GSK3. It has been shown that GSK3 phosphorylates Thr-58 residue of c-Myc and that this enhances the degradation of cMyc protein (Sears et al., 1999; Gregory and Hann, 2000; Sears et al., 2000; Gregory et al., 2003) . Thus, it is conceivable that Akt also upregulates c-Myc levels by inhibiting its degradation. Consistent with these results, we here observed that PRL-stimulation of W53 cells caused GSK3 phosphorylation at Thr-58; this phosphorylation was abolished by inhibition of Akt activation. Moreover, when GSK3 was inhibited by lithium or by SB415286, basal and PRL-induced levels of c-Myc were increased as compared to untreated cells, demonstrating the role of Akt/GSK3 in the control of c-Myc expression.
In other model systems, Akt has also been implicated in the control of c-Myc expression through other signalling cascades. For example, stimulation of growth hormone receptor results in the upregulation of c-Myc through activation of the Jak2/PI3K/Akt/NF-kB pathway (Jeay et al., 2001) , Bcr-Abl upregulates c-Myc through PI3K-Akt (Skorski et al., 1997) , and erythropoietin activates c-Myc expression through both Akt and Erk1/2 (Chen and Sytkowski, 2001) . We have shown that Erk1/2 is not involved in c-Myc upregulation by PRL. PDGF also controls c-Myc expression by activating the AP-1 site of its promoter through JNK and Jun proteins (Iavarone et al., 2003) . In PRLstimulated W53 cells, we also observed activation of JNK in a SFK-independent manner, as it was insensitive to PP1/PP2 (data not shown). We cannot therefore exclude the contribution of JNK/Jun pathway in our model system, although through a pathway different from that we have studied here.
Stat3 transcription factor is also involved in activating expression of genes implicated in cell cycle progression such as c-Myc, cyclin D, c-Fos, etc, (Bromberg et al., 1999; Catlett-Falcone et al., 1999; Barre et al., 2003) . In our model PRL stimulated Stat3 phosphorylation in an SFK-dependent manner, as its activation was sensitive to PP1, but independent of PI3K/Akt, as it was not inhibited by LY294002 (data not shown). However, no effects were detected in c-Myc transcription when DStat3 (a truncated mutant lacking the transactivation domain that acts as a dominant-negative form of Stat3) (Mui et al., 1996) was cotransfected with the c-Myc promoter luciferase construct (data not shown), indicating that in W53 cells Stat3 may not be involved in regulating c-Myc transcription, or that a cofactor in the transcription activating complex is missing in this model.
In agreement with these findings, we observed that the overexpression of c-Myc compensated, at least in part, the proliferation arrest caused by LY294002 inhibition of PI3K/Akt in PRL-stimulated cells.
An abundance of evidence has amassed in recent years, demonstrating that Akt activity is a major determinant for cell survival. However, the involvement of c-Myc in Akt-mediated survival depended on the cell type under study. In some models, and particularly fibroblasts, c-Myc induces apoptosis in cells deprived of growth factors (Hoffman and Liebermann, 1998; Grandori et al., 2000) . Moreover, in fibroblasts it has been shown that the activation of Akt does not upregulate c-Myc expression but suppresses c-Mycinduced apoptosis (Kauffmann-Zeh et al., 1997; Rohn et al., 1998) . In the experiments presented here, c-Myc appears to antagonize the cell growth arrest provoked by PI3K/Akt inhibition. These results are in agreement with the data found in lymphoid cells in vivo (de Alboran et al., 2001; Trumpp et al., 2001; Wendel et al., 2004) and in culture (Wu et al., 1996; Medh et al., 2001) showing that c-Myc and active Akt cooperate for tumorigenesis and survival. Taken together, these results indicate that Akt-Myc is a major signalling pathway for survival in lymphoid cells, suggesting that c-Myc deregulation provides growth advantage to lymphoid cells. Thus, our results are consistent with the high frequency of c-Myc deregulation observed in lymphoid tumours and help to explain the mechanisms for Mycmediated lymphomagenesis.
Materials and methods

Reagents
Tissue culture media, sera, and Trizol were purchased from Life Technologies (Renfrewshire, UK). Ovine PRL (PRL, NIDDK-oPRL-20, 31 IU/mg) was kindly provided by the National Hormone and Pituitary Program of the National Institute of Diabetes and Digestive and Kidney Diseases (Bethesda, MD, USA). BCA protein assay reagent was from Pierce (Rockford, IL, USA). Anti-p70S6K was a gift from G Thomas (Friedrich Miescher Institute). Antibodies against Erk2 (C-14), Stat 5b (C-17), Akt1/2 (H-136), HA (Y-11), FKHRL1 (Foxo3, , and c-Myc (C-19 and 9E10) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Parp mouse mAb was from Biomol Research Laboratories. Antibodies against pMek1/2, pErk1/2 (pp42/ 44), pp70S6K, GSK3b, p-GSK3b (Ser 9), and pAkt (Ser473) were from New England Biolabs (Beverly, MA, USA), and p-FKHRL1 (p-Foxo3, Thr 32) from Upstate (Lake Placid, NY, USA). The anti-a-tubulin antibody, bovine serum albumin (BSA), Triton X-100, Hoechst 33342, and LiCl were purchased from (St Louis, MS, USA). The fluorescein (FITC)-conjugated AffiniPure F(ab 0 ) 2 -fragment goat anti-rabbit IgG antibody was from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). The secondary antibodies horseradish-peroxidase-conjugated were purchased from Biosource International (Camarillo, CA, USA). The enhanced chemiluminiscence (ECL) kit, radiochemicals, and the Oligolabeling kit were from Amersham Pharmacia Biotech (Buckinghamshire, UK). PP1, LY294002, and rapamycin were obtained from Alexis Biochemicals (San Diego, CA, USA). SB415286 was from Tocris Cookson (Ellisville, MO, USA). PD184352 was a gift from Philip Cohen (MRC Protein Phosphorylation Unit, University of Dundee, Scotland). All inhibitors were dissolved in DMSO.
Cell culture and transfection
The W53 cells were cultured in RPMI-1640 containing 10% FCS, 4 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 mg/ml), and 5 ng/ml of PRL as previously described (Morales et al., 1999) . The W53-Akt-wt and W53-Akt-myr cell lines were obtained by electroporation (960 mF and 300 V) of pcDNA3 containing the wild-type and myristoylated forms of HA-tagged Akt, respectively (B Burgerin, University of Utrecht) into W53 cells (2 Â 10 6 cells/sample) using a BioRad Gene Pulser (Bio-Rad Laboratories, Hercules, CA, USA). Similarly, W53 cells expressing c-Myc cloned were also obtained by electroporation as above. The transfected plasmid was pCEFL-Myc, which carries human c-Myc cDNA cloned in the expression vector pCEFL (Mauleon et al., 2004) . Transfected cells were cultured for 48 h prior to selection with 2 mg/ml of G418 to obtain a pool of resistant cells. To generate a W53 cell line expressing Akt-CAAX Box under the inducible control of tetracycline promoter (Tet-On System), Akt-CAAX Box mutant was excised from pCMV5 (B Burgerin, University of Utrecht) (Dufner et al., 1999) by digestion with EcoRI, and ligated into the vector pTet-splice (Gibco-BRL). Then BaF-3 cells that constitutively express rt-Tet activator (Klucher et al., 1998) were cotransfected by electroporation (960 mF and 300 V) with pTet-Splice-Akt-CAAX Box (20 mg) and PRL receptor (the long form of the PRLR from rat liver) (4 mg) (Morales et al., 1999) . At 36 h after transfection, cells were seeded into 96-well plates (10 4 cells/well) in medium containing IL-3 and puromycin (2 mg/ml). Puromycin-resistant cells were expanded and screened for expression of Akt-CAAX Box after 16 h of treatment with doxicycline (2 mg/ml) by Western blot using anti-Akt antibody. Positive cells were then selected for growing in PRL-containing medium in the absence of IL-3. The initial concentration of PRL was 500 ng/ml, and subsequently the concentration was progressively decreased to 5 ng/ ml. Cells growing at this PRL concentration were tested again for inducible expression of Akt-CAAX Box by doxycycline as above. Cells with similar induction were pooled and used for experiments. This cell line has been always maintained in culture using Tet-free foetal bovine serum (Tet System Approved FBS, BD Biosciences Clontech, Palo Alto, CA, USA) to avoid possible contamination of normal foetal bovine serum with tetracycline. For transient transfections, W53 cells were electroporated (960 mF and 300 V) with 10 mg of the c-Myc promoter luciferase reporter construct (Lee and Ziff, 1999) together with pSG5-FKHRL1-A3 (provided by Boudewijn (University Medical Center, Utrecht, Nederlands) (Dijkers et al., 2002) , or the empty plasmid as control. After transfection, cells were cultured in the absence or presence of PRL (100 ng/ml) for 24 h. Cells were harvested, lysed with the commercially luciferase lysis buffer (Promega, Madison, USA), the cell extracts were normalized for the protein concentration, and the luciferase activity was measured.
Analysis of the cell cycle by PI DNA staining Cell cycle was analysed by flow cytometry staining DNA with PI as described previously (Nicoletti et al., 1991) . Briefly, cells were collected by centrifugation at 400 g for 5 min at room temperature and fixed in 1 ml of PBS-70% ethanol for at least 1 h at 41C. Fixed cells were washed in PBS and then incubated in 0.5 ml of PBS containing 50 mg/ml PI, 100 mg/ml de RNAase (Sigma Chemicals Co) for 30 min at room temperature in the dark. Cells were then analysed by a FACScan flow cytometry (Becton Dickinson Co) collecting PI fluorescence signals through a 575 nm pass filter. The minimum number of acquired cells/sample was always 10 4 cells. To calculate the percentage of cells in G0-G1, S and G2-M phases of the cell cycle, the histograms were analysed by the ModFitLT V2.0 computer program.
Immunofluorescence microscopy analysis
To study the intracellular localization of Akt and FKHRL1, W53 cells were stimulated with PRL (100 ng/ml) for 15 min. Control and treated cells were then washed once in ice-cold PBS, then transferred onto a coverslip by cytospin, fixed in 100% methanol for 10 min at À201C, and washed three times for 5 min with PBS containing 0.1% Triton X-100 (PBS-T) at room temperature. Samples were incubated with blocking buffer (2% BSA and 3% normal goat serum in PBS-T) for 30 min at room temperature. Incubations with primary antibodies (dilution 1 : 50 in PBS-2% BSA) were performed for 1 h at 371C. Coverslips were washed twice for 5 min with PBS-T, and then incubated with a goat anti-rabbit IgG FITCconjugated antibody (dilution 1 : 100 in PBS-2% BSA) for 1 h at 371C. Samples were subsequently washed three times for 5 min in PBS and stained with 10 mM Hoechst 33342 for 10 min at 371C. After mounting in Mowiol medium, coverslips were examined on an Axiovert 200 inverted microscopy (Zeiss, Gottingen, Germany) equipped with a colour digital camera (Spot RT Slider) (Diagnostic Instruments, Sterling Heights, MI, USA). Photographs were taken by using a Â 63/1.40 oil Plan-Apochromat objective.
Proliferation assays
W53 cells were plated onto 96-well flat-bottomed plates (5 Â 10 4 cells/well) and cultured for 24 h in RPMI-1640 supplemented with 10% FCS and 5 ng/ml PRL, in the presence of different concentrations of the inhibitors (PD184352, LY294002, and rapamycin), or with the equivalent amounts of solvent (DMSO, dilution 1 : 1000) as a control. Each well was pulsed for 4 h with 1 mCi [ 3 H]thymidine. Cells were harvested onto glass fibre filter paper. Filters were dried and counted in a solid scintillation counter (1450 Microbeta Wallac LKB, Turku, Finland). All samples were assayed in triplicate.
Cell stimulation and Western blot analysis
W53 cells were washed with RPMI-1640 to remove PRL and cultured overnight with medium containing 1% horse serum. Next day, cells were pretreated for 2 h with the inhibitors, or with the equivalent volume of DMSO (dilution 1 : 1000), as a control. Cells were stimulated with PRL (100 ng/ml) for different periods of time. Cells were collected and washed once in ice-cold PBS stopped stimulation and lysed for 30 min at 41C with 1 ml per 2 Â 10 7 cells of lysis buffer (LB: 1 Â PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 1 mM phenantroline, 1 mM benzamidine hydrochloride, 1 mM iodoacetamide). The total cell lysates was centrifuged at 15 000 g for 30 min at 41C. Protein concentration in the supernatants was determined by the BCA protein assay, and then they were compensated with LB. They were boiled in 1 Â SDS sample buffer (62.5 mM Tris-HCl (pH 6.8), 5% 2-mercaptoethanol, 2% SDS, 10% glycerol) and stored at À801C until further use.
For Western blotting analysis, samples were subjected to SDS-PAGE and transferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA). Filters were blocked with 5% fat-free dried milk (Fluka BioChemika, Neu-Ulm, Switzerland) in TTBS (10 mM Tris-HCl (pH 7.4), 0.1% Tween-20) or with 5% BSA in TTBS for immunodetections with antiphospho antibodies. Membranes were incubated with the selected primary antibody in blocking buffer, washed three times with TTBS, and further incubated with the suitable horseradish peroxidase-conjugated anti-species-specific antibody. ECL visualized protein bands (Amersham Pharmacia Biotech, Buckinghamshire, UK).
Northern blot analysis
W53 cultures (5 Â 10 5 cells/ml) were maintained overnight in RPMI-1640 medium supplemented with 1% horse serum. Cells were pretreated for 2 h with the inhibitors, or with the equivalent volume of DMSO (dilution 1 : 1000), as a control. Cultures were then stimulated with PRL (100 ng/ml), aliquots of cells (12 Â 10 6 ) were taken at different times, and total RNA was isolated using Tryzol. RNA was fractionated by electrophoresis through a 1% agarose gel containing 6% formaldehyde and transferred onto Nytran membranes (Schleicher & Schuell, Dassel, Germany) by capillary blotting. Blots were hybridized with cDNA probes labelled with the Oligolabelling kit using 25 mCi [a-32 P]dCTP (3000 Ci/mmol; Amersham Pharmacia Biotech). After several washes, the hybridization signals on the blotted membrane were visualized by autoradiography. Specific probes were used for Northern hybridization for c-fos and c-myc as described previously.
